#LYMPHIR #Citius Oncology #ASCO 2026

Citius Oncology Showcases LYMPHIR® Data at ASCO 2026

Citius Oncology, Inc. (Nasdaq: CTOR), a biopharmaceutical company dedicated to oncology, recently made headlines with the announcement of their presentation regarding the Phase 1 combination study of LYMPHIR® (denileukin diftitox-cxdl) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This pivotal event will be held from May 29 to June 2, 2026, in Chicago, Illinois.

Background on LYMPHIR® and Combination Therapy

LYMPHIR®, a targeted immune therapy, is currently marked for its use in treating relapsed or refractory cutaneous T-cell lymphoma (CTCL) after prior systemic therapy. The recent study, initiated by investigators from the University of Pittsburgh Medical Center (UPMC), evaluates the safety and preliminary effectiveness ofLYMPHIR in conjunction with pembrolizumab (KEYTRUDA®), a PD-1 immune checkpoint inhibitor. This study aims to better elucidate the potential of LYMPHIR to enhance the effectiveness of checkpoint inhibitors in treating not merely CTCL but potentially other tumor types as well.

The significance of this Phase 1 trial cannot be overstated. It focuses on the response rate of 24% and an impressive average duration of response noted at 21.1 months among responders, marking a noteworthy development in the domain of immunotherapy for gynecologic cancers.

ASCO Presentation Details

The study is set to be featured in a poster session at ASCO, signifying its recognition among elite cancer research submissions, as it was selected from over 8,500 entries. The abstract titled “Depletion of T-regulatory cells by denileukin diftitox-cxdl in Combination with Pembrolizumab in Relapsed/Refractory Gynecologic Malignancies Phase 1 Study Results